Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 8/2015

01-08-2015 | Anaphylaxis and Drug Allergy (DA Khan and M Castells, Section Editors)

Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association

Authors: Patrizia Bonadonna, Massimiliano Bonifacio, Carla Lombardo, Roberta Zanotti

Published in: Current Allergy and Asthma Reports | Issue 8/2015

Login to get access

Abstract

Clinical manifestations of mastocytosis in adults comprise signs and symptoms linked to mast cell (MC) activation, including anaphylaxis. Depending on MC burden, adults can be diagnosed with systemic mastocytosis, when the WHO criteria are fulfilled, or with other clonal MC disorders, characterized by MC mediator symptoms and demonstration of activating KIT mutations and/or expression of CD25 on MCs. There is a specific link between mastocytosis and hymenoptera venom allergy (HVA): the reported frequency of HVA in mastocytosis is 20–50 % and raises to 60–80 % in patients affected by indolent systemic mastocytosis without skin lesions. The presentation of HVA characterized by severe hypotension in the absence of urticarial or angioedema is typical in patient with an underlying MC disorder, even in the presence of normal baseline serum tryptase levels.
Literature
1.
Horny HP et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. p. 54–63.
2.
Valent P et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Investig. 2007;37:435–53.CrossRef
3.
Bonadonna P et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123:680–6.PubMedCrossRef
4.
Bonadonna P et al. How much specific is the association between hymenoptera venom allergy and mastocytosis? Allergy. 2009;64:1379–82.PubMedCrossRef
5.
Alvarez-Twose I et al. Clinical, biological and molecular characteristics of systemic mast cell disorders presenting with severe mediator-related symptoms. J Allergy Clin Immunol. 2010;125:1269–78.PubMedCrossRef
6.
7.
Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin N Am. 2014;34:283–95.CrossRef
8.
Zanotti R et al. Somatic D816 KIT mutation in a case of adult onset familial mastocytosis. J Allergy Clin Immunol. 2013;131:605–7.PubMedCrossRef
9.
Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol. 2007;138:12–30.PubMedCrossRef
10.
van Doormaal JJ et al. Prevalence of indolent systemic mastocytosis in a Dutch region. J Allergy Clin Immunol. 2013;131:1429–31.PubMedCrossRef
11.
12.
Bonifacio M, et al. Epidemiology of mastocytosis in adults based on a multidisciplinary diagnostic approach. Haematologica (EHA annual meeting abstracts). 2013;98(s1):348.
13.
Sonneck K et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol. 2006;142:158–64.PubMedCrossRef
14.••
Valent P et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157:215–25. Consensus paper from a group of experts defining criteria for diagnosis of mast cell disorders and proposing a global unifying classification of all mast cell disorders. These criteria help to diagnose mast cell activation syndromes.PubMedCentralPubMedCrossRef
15.
Valent P. Mast cell activation syndromes: definition and classification. Allergy. 2013;68:417–24.PubMedCrossRef
16.••
Alvarez-Twose I et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol. 2014;133:520–8. Very interesting study where the authors underline that patients with Indolent Systemic Mastocytosis without skin lesions associated with insect-induced anaphylaxis present very characteristic clinical and serological features compared to other patients with ISM.PubMedCrossRef
17.
Akin C et al. Demonstration of an aberrant mast cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood. 2007;110:2331–3.PubMedCentralPubMedCrossRef
18.
Pardanani A et al. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia. 2013;27:2091–4.PubMedCrossRef
19.
Picard M, Giavina-Bianchi P, Mezzano V, Castells M. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther. 2013;35:548–62.PubMedCrossRef
20.
Gülen T, Hägglund H, Sander B, Dahlén B, Nilsson G. The presence of mast cell clonality in patients with unexplained anaphylaxis. Clin Exp Allergy. 2014;44:1179–87.PubMedCrossRef
21.
Escribano L et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom. 2004;58:1–8.PubMedCrossRef
22.
De Matteis G, et al. The impact of sensitive KIT D816V detection on recognition of indolent systemic mastocytosis. Leuk Res. 2014.
23.
Sánchez-Muñoz L et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol. 2011;24:1157–68.PubMedCrossRef
24.
Lim KH et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727–36.PubMedCrossRef
25.
Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol. 2012;157:399–405.PubMedCrossRef
26.
Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004;57:604–8.PubMedCentralPubMedCrossRef
27.
Nagata H et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92:10560–4.PubMedCentralPubMedCrossRef
28.
Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res. 2001;25:571–6.PubMedCrossRef
29.
Iwaki S, Spicka J, Tkaczyk C, Jensen BM, Furumoto Y, Charles N, et al. Kit- and Fc epsilonRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cells. Cell Signal. 2008;20:195–205.PubMedCentralPubMedCrossRef
30.
Florian S et al. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol. 2005;136:273–80.PubMedCrossRef
31.
Gonzalez de Olano D et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy. 2007;37:1547–55.
32.
Gulen T, Hagglund H, Dahlen B, Nilsson G. High prevalence of anaphylaxis in patients with systemic mastocytosis: a single-centre experience. Clin Exp Allergy. 2014;44:121–9.PubMedCrossRef
33.
Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226–32.PubMedCrossRef
34.
Muraro A et al. EAACI Food Allergy and Anaphylaxis Guidelines Group. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69:1026–45.PubMedCrossRef
35.
Lieberman P et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol. 2006;97:596–602.PubMedCrossRef
36.
Strait RT, Morris SC, Smiley K, Urban Jr JF, Finkelman FD. IL-4 exacerbates anaphylaxis. J Immunol. 2003;170:3835–42.PubMedCrossRef
37.
38.
Bilò BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol. 2008;8:330–7.PubMedCrossRef
39.
40.
Severino MG, Campi P, Macchia D, Manfredi M, Turillazzi S, Spadolini I, et al. European Polistes venom allergy. Allergy. 2006;61:860–3.PubMedCrossRef
41.
Müller UR, Horat W, Wüthrich B, Conroy M, Reisman RE. Anaphylaxis after Hymenoptera sting in three patients with urticaria pigmentosa. J Allergy Clin Immunol. 1983;72:685–9.PubMedCrossRef
42.
Kors JW, van Doormaal JJ, de Monchy JG. Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis. J Intern Med. 1993;233:255–8.PubMedCrossRef
43.
Oude Elberink JNK, de Moncky JGR, Kors JW, van Doormaal JJ, Dubois AE. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol. 1997;99:153–4.PubMedCrossRef
44.
Fricker M, Helbling A, Schwartz L, Müller U. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J Allergy Clin Immunol. 1997;100:11–5.PubMedCrossRef
45.
Biedermann T, Ruëff F, Sander CA, Przybilla B. Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels. Br J Dermatol. 1999;141:1110–2.PubMedCrossRef
46.
Matito A et al. Anaphylaxis as a clinical manifestation of clonal mast cell disorders. Curr Allergy Asthma Rep. 2014;14:450.PubMedCrossRef
47.
Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy. 2003;33:1216–20.PubMedCrossRef
48.
Rueff F et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase- a study of the European Academy of Allergology and Clinical Immunology Interest Group of Insect venom hypersensitivity. J Allergy Clin Immunol. 2009;129:1047–54.CrossRef
49.
Bonadonna P, Lombardo C, Zanotti R. Mastocytosis and allergic diseases. J Investig Allergol Clin Immunol. 2014;24:288–97.PubMed
50.
Bonadonna P, Zanotti R, Müller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol. 2010;10:347–53.PubMedCrossRef
51.•
Van Anrooij B et al. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. J Allergy Clin Immunol. 2013;132:125–30. Very good study that confirm that HVA-induced anaphylaxis is rare in patients with aggressive subtypes of SM, who harbor the highest mast cell load; this observation challenges the opinion that the risk of hymenoptera venom anaphylaxis increases with increasing mast cell load.PubMedCrossRef
52.
Niedoszytko M et al. Gene expression profile, pathways, and transcriptional system regulation in indolent systemic mastocytosis. Allergy. 2011;66:229–37.PubMedCrossRef
53.
Teodosio C et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol. 2010;125:719–26.PubMedCrossRef
54.
Rossini M et al. Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin N Am. 2014;34:383–96.CrossRef
55.
Escribano L et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry Part B. 2004;58B:1–8.CrossRef
56.
Perbellini O et al. Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders. Cytometry B Clin Cytom. 2011;80:362–8.PubMedCrossRef
57.
Arock M, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015.
58.••
Valent P et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy. 2014;69:1267–74. This very important paper proposed for the first time a very useful algorythm for patient with suspected mastocytosis and without skin lesions including also patients with tryptase levels lower than 15-20 ng/mL. Screening includes clinical symptoms, characteristic of anaphylaxis (REMA score) and evaluation of KIT mutation in the peripheral blood.PubMedCrossRef
59.
Broesby-Olsen S, Mastocytosis Centre Odense University Hospital (MastOUH) and Odense Research Centre for Anaphylaxis, et al. Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood. J Allergy Clin Immunol. 2015;135:262–4.PubMedCrossRef
60.
Bokanovic D, Aberer W, Griesbacher A, Sturm GJ. Prevalence of hymenoptera venom allergy and poor adherence to immunotherapy in Austria. Allergy. 2011;66:1395–6.PubMedCrossRef
61.
Incorvaia C et al. Prevalence of allergic reactions to Hymenoptera stings in northern Italy. Eur Ann Allergy Clin Immunol. 2004;36:372–4.PubMed
62.
Zanotti R, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol. 2015.
Metadata
Title
Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association
Authors
Patrizia Bonadonna
Massimiliano Bonifacio
Carla Lombardo
Roberta Zanotti
Publication date
01-08-2015
Publisher
Springer US
Published in
Current Allergy and Asthma Reports / Issue 8/2015
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-015-0550-0

Other articles of this Issue 8/2015

Current Allergy and Asthma Reports 8/2015 Go to the issue

Basic and Applied Science (PJ Bryce, Section Editor)

Regulation of Adaptive Immunity in Health and Disease by Cholesterol Metabolism

Food Allergy (T Green, Section Editor)

Food Protein-Induced Enterocolitis Syndrome, Allergic Proctocolitis, and Enteropathy

Rhinosinusitis (M Mullol, Section Editor)

Humoral Primary Immunodeficiencies in Chronic Rhinosinusitis

Erratum

Erratum to: Technological Innovations for High-Throughput Approaches to In Vitro Allergy Diagnosis

Food Allergy (T Green, Section Editor)

Oral Food Challenges: The Design must Reflect the Clinical Question

Rhinitis (JJ Oppenheimer and J Corren, Section Editors)

The Future of Sublingual Immunotherapy in the United States